The history of Curasight

Curasight was founded in 2013 in Denmark based on a strong understanding of nuclear medicine and more than a decade of research at Copenhagen University Hospital, Rigshospitalet, and the University of Copenhagen, where the potential of targeting the urokinase-type plasminogen activator receptor (uPAR) in solid tumors with radioligands was pioneered.

Led by Professor Andreas Kjær (CSO & Co-founder), the research demonstrated how uPAR could be used not only to visualize aggressive cancer biology through PET imaging but also as a highly selective target for radioligand therapy (RLT) across multiple solid tumor types. These insights formed the basis for Curasight’s theranostic approach and the inception of the company.

Since its establishment, Curasight has focused on validating and advancing its first-in-class uPAR-based RLT platform, uTREAT^®, supported by the uPAR imaging agent uTRACE^®. Built on the same uPAR-targeting PET ligand, this theranostic approach enables the identification, targeting, and elimination of aggressive solid tumors with unmatched precision across multiple indications. uTRACE^® has been evaluated in nine clinical studies involving more than 450 patients across eight solid tumor types, generating a robust human evidence base for uPAR as a pan-tumor aggressiveness target.

uTREAT^® entered the clinic in a first-ever human Phase 1 trial, treating patients with glioblastoma in December 2025. The company’s diagnostic platform uTRACE^® is currently in a Phase 2 trial in prostate cancer under a partnership signed in 2023 with the leading radiopharmaceutical company Curium Inc.

Curasight was listed in 2020 on the Spotlight Stock Market.